Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG
Bronwyn Bosch, Godspower Akpomiemie, Nomathemba Chandiwana, Simiso Sokhela, Andrew Hill, Kaitlyn McCann, Ambar Qavi, Manya Mirchandani, François Venter
Abstract
Participants randomized to first-line tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, or TDF/FTC/efavirenz (EFV) for 192 weeks were then switched to TDF/lamivudine (3TC)/DTG for 52 weeks. Participants switching either TAF/FTC + DTG or TDF/FTC/EFV to TDF/3TC/DTG showed statistically significant reductions in weight, low-density lipoprotein, triglycerides, glucose and glycated hemoglobin.
Topics & Concepts
Tenofovir alafenamideEmtricitabineDolutegravirEfavirenzMedicineLamivudinePharmacologyVirologyHuman immunodeficiency virus (HIV)Viral loadHepatitis B virusVirusAntiretroviral therapyHIV-related health complications and treatmentsHIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions